6,088 Shares in Sanofi (NASDAQ:SNY) Purchased by Bingham Private Wealth LLC

Bingham Private Wealth LLC purchased a new stake in shares of Sanofi (NASDAQ:SNY - Free Report) in the first quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 6,088 shares of the company's stock, valued at approximately $338,000.

A number of other large investors also recently bought and sold shares of the business. BKM Wealth Management LLC lifted its position in Sanofi by 8.5% during the 1st quarter. BKM Wealth Management LLC now owns 10,358 shares of the company's stock valued at $574,000 after acquiring an additional 813 shares during the period. Willner & Heller LLC lifted its position in Sanofi by 15.1% during the 1st quarter. Willner & Heller LLC now owns 6,109 shares of the company's stock valued at $339,000 after acquiring an additional 800 shares during the period. Pzena Investment Management LLC purchased a new position in Sanofi during the 1st quarter valued at about $299,000. Bailard Inc. lifted its position in Sanofi by 69.5% during the 1st quarter. Bailard Inc. now owns 27,736 shares of the company's stock valued at $1,538,000 after acquiring an additional 11,377 shares during the period. Finally, Verdence Capital Advisors LLC increased its stake in Sanofi by 11.8% during the 1st quarter. Verdence Capital Advisors LLC now owns 34,546 shares of the company's stock valued at $1,916,000 after purchasing an additional 3,637 shares in the last quarter. 14.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Price Performance

NASDAQ:SNY traded up $1.51 during trading hours on Wednesday, hitting $50.26. 846,000 shares of the stock traded hands, compared to its average volume of 2,304,131. The company has a quick ratio of 0.69, a current ratio of 1.37 and a debt-to-equity ratio of 0.16. Sanofi has a 1 year low of $45.80 and a 1 year high of $60.12. The company has a market cap of $123.26 billion, a price-to-earnings ratio of 17.95, a price-to-earnings-growth ratio of 1.09 and a beta of 0.48. The stock has a 50 day moving average price of $49.65 and a 200 day moving average price of $52.13.

Sanofi (NASDAQ:SNY - Get Free Report) last released its earnings results on Thursday, April 24th. The company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.90 by $0.04. Sanofi had a net margin of 14.56% and a return on equity of 17.15%. The firm had revenue of $10.41 billion for the quarter, compared to the consensus estimate of $9.79 billion. During the same quarter in the previous year, the firm earned $1.78 earnings per share. The company's quarterly revenue was down 11.0% compared to the same quarter last year. Sell-side analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on SNY shares. Morgan Stanley set a $56.00 price objective on shares of Sanofi in a research note on Monday, June 2nd. Hsbc Global Res upgraded shares of Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. BNP Paribas started coverage on shares of Sanofi in a research note on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price objective for the company. Barclays restated an "overweight" rating on shares of Sanofi in a research note on Wednesday, July 2nd. Finally, Guggenheim restated a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Three equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, Sanofi presently has a consensus rating of "Buy" and an average price target of $61.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.